{"id":150684,"date":"2020-03-29T18:50:52","date_gmt":"2020-03-29T16:50:52","guid":{"rendered":"https:\/\/clinical.r-biopharm.com\/indikation\/therapeutisches-drug-monitoring\/tdm-checker\/"},"modified":"2022-04-12T13:04:25","modified_gmt":"2022-04-12T11:04:25","slug":"tdm-checker","status":"publish","type":"page","link":"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/tdm-checker\/","title":{"rendered":"TDM Checker"},"content":{"rendered":"<div class=\"wpb-content-wrapper\">[vc_row][vc_column width=&#8220;2\/3&#8243;][vc_column_text css=&#8220;.vc_custom_1649761461683{margin-bottom: 0px !important;}&#8220;]Monoklonale Antik\u00f6rper gegen Entz\u00fcndungsmediatoren, sogenannte Biologika oder Biosimilars, werden seit mehr als 10 Jahren zur Behandlung chronisch-entz\u00fcndlicher Darmerkrankungen (CED) wie Morbus Crohn und der Colitis ulcerosa eingesetzt.<\/p>\n<p>F\u00fcr eine optimale Behandlung, ist es wichtig die Medikamentenkonzentration (Through Level) im Blut des Patienten zu \u00fcberpr\u00fcfen. Anhand der gemessenen Medikamentenkonzentration kann die Therapie optimiert werden.<\/p>\n<p>R-Biopharm stellt den TDM-Checker und die Behandlung mit Infliximab auf der Grundlage der Taxittrial-Ergebnisse ein.<\/p>\n<p>Es gibt mehr Biologika \/ Biosimilars als Infliximab, deshalb haben wir entschieden, dass der BridgeIBD Biologic-Therapy-Optimizer ein besseres Werkzeug f\u00fcr Sie als medizinisches Fachpersonal ist.<\/p>\n<p>Der folgende Link f\u00fchrt sie zu einem interaktiven Tool, das Fachkr\u00e4ften des Gesundheitswesens Hilfestellung bei der Interpretation der gemessenen Konzentration von Arzneimitteln und Anti-Arzneimittel-Antik\u00f6rpern geben soll. Hier finden sie u.a. Empfehlungen f\u00fcr Infliximab (Remicade\u00ae), Adalimumab (Humira\u00ae), Vedolizumab (Entyvio\u00ae), Golimumab (Simponi\u00ae) und Ustekinumab (Stelara\u00ae). Und die Biosimilars f\u00fcr Infliximab (Remsima\u00ae, Inflectra \u00ae, Flixabi\u00ae, Zessly\u00ae), Adalimumab (Amgevita\u00ae, Amsparity\u00ae, Hefiya\u00ae, Hulio\u00ae, Hyrimoz\u00ae, Idacio\u00ae, Imraldi\u00ae, Yufluma\u00ae)<\/p>\n<p>Die BRIDGe-Gruppe ist ein Zusammenschluss von Gastroenterologen, die Experten auf dem Gebiet der CED-Patientenversorgung sind und sich auf die patientenzentrierte klinische CED-Forschung konzentrieren.<\/p>\n<p><em>R-Biopharm hat von der BridgeIBD-Gruppe die Erlaubnis erhalten, den Link zum BridgeIBD Biologic-Therapy-Optimizer zu platzieren.<\/em><\/p>\n<p>Reference:<\/p>\n<p><a href=\"https:\/\/www.cghjournal.org\/article\/S1542-3565(19)30301-5\/pdf\" target=\"_blank\" rel=\"noopener\">Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases<\/a> Konstantinos Papamichael, Adam S. Cheifetz, Gil Y. Melmed, Peter M. Irving, Niels Vande Casteele, Patricia L. Kozuch, Laura E. Raffals, Leonard Baidoo, Brian Bressler, Shane M. Devlin, Jennifer Jones, Gilaad G. Kaplan, Miles P. Sparrow, Fernando S. Velayos, Thomas Ullman and Corey A. Siegel[\/vc_column_text][vc_row_inner css=&#8220;.vc_custom_1649233412817{background-color: #e3e5e6 !important;}&#8220;][vc_column_inner width=&#8220;1\/2&#8243;][vc_empty_space height=&#8220;16px&#8220;][mk_image src=&#8220;https:\/\/devclinical.r-biopharm.com\/wp-content\/uploads\/2022\/04\/screenshot_bridge.jpg&#8220; image_size=&#8220;full&#8220;][\/vc_column_inner][vc_column_inner width=&#8220;1\/2&#8243;][vc_empty_space height=&#8220;16px&#8220;][vc_column_text css=&#8220;.vc_custom_1649233257865{margin-bottom: 0px !important;}&#8220;]\n<h3>Interaktiv: TDM<\/h3>\n<p>Das interaktive Tool von BRIDGe, das Ihnen hilft, auf der Grundlage der gemessenen Arzneimittelkonzentrationen die richtige Therapieentscheidung zu treffen.[\/vc_column_text][vc_btn title=&#8220;Jetzt ausprobieren&#8220; style=&#8220;classic&#8220; shape=&#8220;square&#8220; color=&#8220;inverse&#8220; link=&#8220;url:https%3A%2F%2Fwww.bridgeibd.com%2Fbiologic-therapy-optimizer|target:_blank&#8220;][\/vc_column_inner][\/vc_row_inner][\/vc_column][vc_column width=&#8220;1\/3&#8243;][mk_mini_callout title=&#8220;TDM&#8220; button_text=&#8220;Mehr erfahren&#8220; button_url=&#8220;https:\/\/devclinical.r-biopharm.com\/indications\/therapeutic-drug-monitoring\/&#8220;]oder Therapeutic Drug Monitoring bedeutet die Messung der Medikamentenspiegel im Blut des Patienten, um die Dosis individuell an die Bed\u00fcrfnisse des Patienten anzupassen. Dadurch kann das Medikament optimal wirken und die Therapiekosten k\u00f6nnen gesenkt werden.[\/mk_mini_callout][\/vc_column][\/vc_row][vc_row disable_element=&#8220;yes&#8220;][vc_column][vc_tabs][vc_tab title=&#8220;Disclaimer&#8220; tab_id=&#8220;1581342209-1-29&#8243;][vc_column_text css=&#8220;.vc_custom_1592309154874{margin-bottom: 0px !important;}&#8220;]The TDM Checker is a tool intended to provide assistance for health care professionals such as gastroenterologists, laboratory personnel and specialized nurses regarding the interpretation of drug and anti-drug antibody concentrations, as measured using the RIDASCREEN\u00ae and RIDA\u00aeQUICK tests. It is known, that different infliximab and anti-infliximab antibody monitoring assays may report different concentrations due to assay-specific variabilities in performance. It is advisable to use one single assay to measure drug and anti-drug antibodies in patients.<\/p>\n<p>The threshold concentrations of the TDM Checker have been based on trough concentrations during maintenance phase, i.e. the drug and anti-drug antibody concentration just before the next dose administration. Different threshold concentrations may apply for samples withdrawn at peak or intermediate time points.<\/p>\n<p>PLEASE NOTE: The TDM Checker is a supporting tool only and has to be used strictly in conjunction with other clinical, biological and endoscopic findings.<\/p>\n<p>IT DOES NOT REPLACE PROPER CLINICAL JUDGEMENT.<\/p>\n<p>It is recommended to test for drug and anti-drug antibody trough concentrations at consecutive doses to optimize treatment (Dreesen et al. Clinical Pharmacology: Advances and Applications 2017;9:10-111). Please adhere to local guidelines for the management of patients treated with biological drugs.[\/vc_column_text][\/vc_tab][vc_tab title=&#8220;Background&#8220; tab_id=&#8220;1581342209-2-35&#8243;][vc_column_text css=&#8220;.vc_custom_1592312667889{margin-bottom: 0px !important;}&#8220;]Various patient, drug and disease specific characteristics are known to influence treatment outcomes in patients with inflammatory bowel diseases, such as baseline disease activity, treatment adherence and immunogenicity. In addition, higher trough concentrations have been suggested to be associated with response and remission in patients with specific disease phenotypes, such as patients with perianal disease, or when targeting endoscopic healing. The drug and anti-drug antibody concentration should therefore \u2013 in any case &#8211; not be interpreted as the sole indicator of a treatment change and have to be used in the context of the clinical status of the patient and together with other laboratory results.<\/p>\n<p>The TDM Checker has been developed based on consensus statements, appropriateness scores and evidence from pivotal clinical studies. The described situations reflect real-life clinical practice, but may not be entirely representative for each and every individual patient. It is based on the following studies:<\/p>\n<ul>\n<li><a href=\"https:\/\/www.gastrojournal.org\/article\/S0016-5085(15)00253-X\/abstract\" target=\"_blank\" rel=\"noopener noreferrer\">Vande Casteele et al. Gastroenterol 2015. doi: 10.1053\/j.gastro.2015.02.031<\/a><\/li>\n<li><a href=\"https:\/\/www.cghjournal.org\/article\/S1542-3565(16)30195-1\/abstract\" target=\"_blank\" rel=\"noopener noreferrer\">Melmed et al. Clin Gastroenterol Hepatol 2016. doi: 10.1016\/j.cgh.2016.05.010<\/a><\/li>\n<li><a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/apt.14368\" target=\"_blank\" rel=\"noopener noreferrer\">Mitrev et al. Aliment Pharmacol Ther 2017. doi: 10.1111\/apt.14368<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31526960\/\" target=\"_blank\" rel=\"noopener noreferrer\">Imbrechts et al. J Pharm Biomed Anal 2019. doi: 10.1016\/j.jpba.2019.112842<\/a><\/li>\n<\/ul>\n[\/vc_column_text][\/vc_tab][vc_tab title=&#8220;Terms and conditions of use&#8220; tab_id=&#8220;1581343163387-2-4&#8243;][vc_column_text css=&#8220;.vc_custom_1581341342945{margin-bottom: 0px !important;}&#8220;]The TDM Checker is a supporting tool only and has to be used strictly in conjunction with other clinical, biological and endoscopic findings.<\/p>\n<p>IT DOES NOT REPLACE PROPER CLINICAL JUDGEMENT.<\/p>\n<p>Although carefully drafted to the best of its knowledge, the site owner and\/or its affiliates do not assume any liability regarding the content of the TDM Checker tool and\/or any respective results nor provide any warranties whatsoever. The user accepts that the usage of the TDM Checker tool is at his or her complete responsibility and therefore will indemnify and hold harmless the site owner and\/or its affiliates from any claims resulting out of or in connection with the usage of the TDM Checker tool. By clicking the \u201caccept terms and conditions of use\u201d button below, the user claims to have read and to have accepted these terms and conditions of use.[\/vc_column_text][\/vc_tab][\/vc_tabs][\/vc_column][\/vc_row][vc_row disable_element=&#8220;yes&#8220;][vc_column][vc_empty_space][vc_column_text css=&#8220;.vc_custom_1592557279474{margin-bottom: 0px !important;}&#8220;]\n<h3>W\u00e4hlen Sie das Medikament, das Ihr Patient einnimmt (derzeit nur Infliximab verf\u00fcgbar), und los geht&#8217;s!<\/h3>\n[\/vc_column_text][vc_column_text css=&#8220;.vc_custom_1585500648604{margin-bottom: 0px !important;}&#8220;]\n        <div id=\"rbio-decision-tree-quiz\">\n\n            <div class=\"progress\">\n                <div class=\"progress-bar\"><\/div>\n            <\/div>\n\n            <h2><\/h2>\n\n            <p class=\"rbio-decision-tree-note-1\">\n               Please note: If the drug concentration of infliximab is >1 \u00b5g\/mL, anti-drug antibody concentrations will be undetectable using the RIDASCREEN\u00ae Anti-IFX Antibodies. The RIDASCREEN\u00ae Anti-IFX Antibodies is a drug-sensitive test and cannot detect antibodies when infliximab concentrations are present. In addition, following Mitrev et al. there is insufficient evidence for the use of a drug-tolerant assay.\n            <\/p>\n\n            <ul id=\"rbio-decision-tree-choices\"><\/ul>\n\n            <p class=\"rbio-decision-tree-footnote\">* It is recommended to confirm active disease with an objective measure of inflammation (e.g., colonoscopy, imaging, CRP). It is recommended to verify adherence to therapy.<\/p>\n\n            <button id=\"rbio-decision-tree-back\">Back<\/button>\n\n        <\/div>\n\n        <div id=\"rbio-decision-tree-outcome\">\n\n            <h2>Your Choices<\/h2>\n\n            <ul id=\"rbio-decision-tree-answers-list\">\n            <\/ul>\n\n            <h2>Outcome<\/h2>\n\n            <figure>\n                <table id=\"rbio-decision-tree-outcome-table\">\n                    <thead>\n                        <tr>\n                            <th id=\"potential-action\">Potential action<\/th>\n                            <th id=\"recommendation\">Recommendation<\/th>\n                        <\/tr>\n                    <\/thead>\n                    <tbody>\n                    <\/tbody>\n                <\/table>\n            <\/figure>\n\n            <button onClick=\"window.location.reload();\">Restart<\/button>\n        <\/div>\n\n    [\/vc_column_text][vc_empty_space][\/vc_column][\/vc_row]\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column width=&#8220;2\/3&#8243;][vc_column_text css=&#8220;.vc_custom_1649761461683{margin-bottom: 0px !important;}&#8220;]Monoklonale Antik\u00f6rper gegen Entz\u00fcndungsmediatoren, sogenannte Biologika oder Biosimilars, werden seit mehr als 10 Jahren zur Behandlung chronisch-entz\u00fcndlicher Darmerkrankungen (CED) wie Morbus Crohn und der Colitis ulcerosa eingesetzt. F\u00fcr eine optimale Behandlung, ist es wichtig die Medikamentenkonzentration (Through Level) im Blut des Patienten zu \u00fcberpr\u00fcfen. Anhand der gemessenen Medikamentenkonzentration kann die Therapie [&hellip;]<\/p>\n","protected":false},"author":27,"featured_media":0,"parent":73578,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"content-type":"","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>TDM Checker: Damit Sie die richtigen Therapieentscheidungen treffen<\/title>\n<meta name=\"description\" content=\"Der TDM Checker hilft Fachkr\u00e4ften des Gesundheitswesens bei der Interpretation der gemessenen Arzneimittel-Konzentration.\" \/>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TDM Checker: Damit Sie die richtigen Therapieentscheidungen treffen\" \/>\n<meta property=\"og:description\" content=\"Der TDM Checker hilft Fachkr\u00e4ften des Gesundheitswesens bei der Interpretation der gemessenen Arzneimittel-Konzentration.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/tdm-checker\/\" \/>\n<meta property=\"og:site_name\" content=\"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-12T11:04:25+00:00\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"5\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/tdm-checker\/\",\"url\":\"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/tdm-checker\/\",\"name\":\"TDM Checker: Damit Sie die richtigen Therapieentscheidungen treffen\",\"isPartOf\":{\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#website\"},\"datePublished\":\"2020-03-29T16:50:52+00:00\",\"dateModified\":\"2022-04-12T11:04:25+00:00\",\"description\":\"Der TDM Checker hilft Fachkr\u00e4ften des Gesundheitswesens bei der Interpretation der gemessenen Arzneimittel-Konzentration.\",\"breadcrumb\":{\"@id\":\"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/tdm-checker\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/tdm-checker\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/tdm-checker\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/devclinical.r-biopharm.com\/de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Indikation\",\"item\":\"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Therapeutisches Drug Monitoring\",\"item\":\"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"TDM Checker\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#website\",\"url\":\"https:\/\/devdevclinical.r-biopharm.com\/\",\"name\":\"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8\",\"description\":\"A Division of the R-Biopharm Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/devdevclinical.r-biopharm.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TDM Checker: Damit Sie die richtigen Therapieentscheidungen treffen","description":"Der TDM Checker hilft Fachkr\u00e4ften des Gesundheitswesens bei der Interpretation der gemessenen Arzneimittel-Konzentration.","robots":{"index":"noindex","follow":"follow"},"og_locale":"de_DE","og_type":"article","og_title":"TDM Checker: Damit Sie die richtigen Therapieentscheidungen treffen","og_description":"Der TDM Checker hilft Fachkr\u00e4ften des Gesundheitswesens bei der Interpretation der gemessenen Arzneimittel-Konzentration.","og_url":"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/tdm-checker\/","og_site_name":"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","article_modified_time":"2022-04-12T11:04:25+00:00","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"5\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/tdm-checker\/","url":"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/tdm-checker\/","name":"TDM Checker: Damit Sie die richtigen Therapieentscheidungen treffen","isPartOf":{"@id":"https:\/\/devdevclinical.r-biopharm.com\/#website"},"datePublished":"2020-03-29T16:50:52+00:00","dateModified":"2022-04-12T11:04:25+00:00","description":"Der TDM Checker hilft Fachkr\u00e4ften des Gesundheitswesens bei der Interpretation der gemessenen Arzneimittel-Konzentration.","breadcrumb":{"@id":"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/tdm-checker\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/tdm-checker\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/tdm-checker\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/devclinical.r-biopharm.com\/de\/"},{"@type":"ListItem","position":2,"name":"Indikation","item":"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/"},{"@type":"ListItem","position":3,"name":"Therapeutisches Drug Monitoring","item":"https:\/\/devclinical.r-biopharm.com\/de\/indikation\/therapeutisches-drug-monitoring\/"},{"@type":"ListItem","position":4,"name":"TDM Checker"}]},{"@type":"WebSite","@id":"https:\/\/devdevclinical.r-biopharm.com\/#website","url":"https:\/\/devdevclinical.r-biopharm.com\/","name":"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","description":"A Division of the R-Biopharm Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/devdevclinical.r-biopharm.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"}]}},"_links":{"self":[{"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/pages\/150684"}],"collection":[{"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/comments?post=150684"}],"version-history":[{"count":5,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/pages\/150684\/revisions"}],"predecessor-version":[{"id":158582,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/pages\/150684\/revisions\/158582"}],"up":[{"embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/pages\/73578"}],"wp:attachment":[{"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/media?parent=150684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}